Injected trivalent inactivated influenza vaccines are most commonly used throughout the world. Influenza antigen preparation varies between manufacturers.
This issue of the ECDC Communicable Disease Threats Report (CDTR) the period 17-23 March 2024 and includes updates on SARS-CoV-2 variant classification, hepatitis A, pertussis, invasive Group A streptococcal infection, chikungunya, dengue, poliomyelitis, western equine encephalitis and cholera.
In this episode we take a closer look at the data collection for respiratory viruses and why we should take this more seriously than just a cough or a sneeze.
This issue of the ECDC Communicable Disease Threats Report (CDTR) the period 18-24 February 2024 and includes updates on influenza, poliomyelitis, SARS-CoV-2, and an overview of respiratory virus epidemiology in the EU/EEA.
Genetic and antigenic characterization data generated at the Worldwide Influenza Centre for viruses with collection dates after 31 January 2023 until 31 August 2023 informed the WHO influenza vaccine composition meeting (VCM) in September 2023 when recommendations were made for the southern hemisphere (SH) 2024 influenza season.
This issue of the ECDC Communicable Disease Threats Report (CDTR) the period 28 January - 3 February 2024 and includes updates on SARS-CoV-2 variant classification, swine influenza, human cases of co-infection with seasonal influenza and avian influenza, influenza, western equine encephalitis, and an overview of respiratory virus epidemiology in the EU/EEA.
This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 7-13 January 2024 and includes updates on SARS-CoV-2, measles, diphtheria, Middle East respiratory syndrome coronavirus (MERS-CoV) and poliomyelitis.
This report contains genetic and antigenic characterization data generated at the Worldwide Influenza Centre for viruses with collection dates after 31 January 2023 until 31 August 2023.